In December, the Oregon-based company announced the acquisition of Mera Life Sciences. Mera Life holds several psychedelic licenses in Oregon. The company plans to utilize Mera’s St. Vincent and the Grenadines lab to create a scientific research and development division. That entity will explore novel clinical applications for a variety of plant-based psychedelics.
“The acquisition of Mera and its coveted licenses would allow Trippy Oregon to perform high quality psychedelic product research and development, cultivate, extract and process, and export not just Psilocybin, but with compounds such as Ayahuasca, MDMA, DMT, Peyote, Ketamine and many other natural based plants as well,” said Todd Shapiro, CEO and Director of Trippy Oregon, in a news release. “We want to work closely with countries wishing to develop plant and fungus-based remedies – including treatment clinics, and we now understand that St. Vincent and the Grenadines shares our vision.”Red Light Holland will collaborate with Vincenitian entities to import the psychedelic compounds.
The company currently produces, grows and sells “magic” truffles through existing smart shops operators and e-commerce platforms in the Netherlands. Wet psilocybin-containing truffles are legal in the Portland.
Truffles and mushrooms are part of the same fungus but produce different effects. Truffles grow underground as a vegetative colony known as mycelium and are generally smaller and wet. Mushrooms, on the other hand, are the fleshy, spore-bearing fruiting body of a fungus, and typically grow above ground. “Trippy Oregon’s goal is to, over time, help make the relatively unknown ‘magic truffle’ a familiar name across the world,” Shapiro said.
Last June, the company expanded its presence in the recreational truffles market. It partnered with McSmart, one of the Netherland’s prominent truffle manufacturers and distributors to produce psilocybin truffle Micro-dosing Packs. The company’s iMicro-dose packs hit the market shortly thereafter.
The company expanded its presence in the medical psychedelics market with the creation of a new division, called “Scarlette Lillie Science and Innovation.” The division is focused on growing medical-grade psilocybin truffles. The goal is to supply the medical market with naturally occurring, non-synthetic psilocybin, as opposed to synthetic pro-drug compounds currently used in clinical trials.
In September, Scarlette Lillie made its first steps toward that end when it secured a relationship with Jinfiniti Precision Medicine. That partnership will help to investigate the therapeutic possibilities of psilocybin and truffles for the treatment of age-related and psychiatric disorders.
Trippy Oregon is also working to establish an EU GMP-certified truffle production and distribution facility based in the Netherlands.